The broadening use of leflunomide in clinical practice

Hospital Medicine

Volumn 65, Issue 12, 2004, Pages 735-739

  Kiely, Patrick D W ^a  

^a ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; LEFLUNOMIDE; LIVER ENZYME; MERCAPTOPURINE; METHOTREXATE; SALAZOSULFAPYRIDINE; TERIFLUNOMIDE; TSUKUBAENOLIDE;

ALOPECIA; AUTOIMMUNE DISEASE; BLOOD TOXICITY; BONE MARROW TOXICITY; CLINICAL PRACTICE; CLINICAL TRIAL; CROHN DISEASE; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; HUMAN; HYPERTENSION; NAUSEA; PANCREATITIS; PRURITUS; REVIEW; RHEUMATOID ARTHRITIS; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; WEIGHT REDUCTION;

EID: 11844273270     PISSN: 14623935     EISSN: None     Source Type: Journal    
DOI: 10.12968/hosp.2004.65.12.735     Document Type: Review

References (27)

1. Chokkalingam S, Shepherd R, Cunningham F, Eisen S (2002) Leflunomide use in the first 33 months after FDA approval: experience in a national cohort of 3325 patients. Arthritis Rheum 46(Suppl): S538
2. Cohen S, Cannon GW, Schiff M et al (2001) Two-year blinded randomized controlled treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group. Arth Rheum 44:1984-92
3. Emery P, Breedfeld C, Lemmel EM et al (2000) A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology 39: 655-65
4. Emery P, Cannon G, Holden W, Strand V, Schiff M (2002) Results from a cohort of over 40000 rheumatoid arthritis (RA) patients: adverse event profiles of leflunomide, methotrexate and other disease-modifying antirheumatic drugs (DMARDS). Ann Rheum Dis 61(Suppl): 42
5. Erra A, Tomas C, Barcelo P, Vilardell M, Marsal S (2003) Is the recommended dose of leflunomide the best regimen to treat rheumatoid arthritis patients? Rheumatology 42: 1123-4
6. Fairbanks LD, Bofil M, Ruckemann K, Simmonds HA (1995) Importance of ribonucleotide availability to proliferating T-lymphocytes from healthy humans. J Biol Chem 270: 29682-91
7. Haibel H, Rudwaleit M, Braun J, Sieper J (2003) Six months open label leflunomide (LEF) in ankylosing spondylitis. Ann Rheum Dis 62(Suppl): 248
8. Hardinger KL, Wang CD, Schnitzler MA et al (2002) Prospective, pilot, open label, short term study of conversion to leflunomide reverses chronic renal allograft dysfunction. Am J Transplant 2: 867-71
9. Kalden JR, Schattenkirchner M, Sorensen H et al (2003) The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five-year follow up study. Arthritis Rheum 48: 1513-20
10. Kaltwasser JP, Nash P, Gladman D et al (2004) Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis. Arthritis Rheum 50: 1939-50
11. Kiely PD, Johnson DM (2002) Infliximab and leflunomide combination therapy in rheumatoid arthritis: an open-label study. Rheumatology 41: 631-7
12. Kremer JM, Genovese MC, Cannon GW et al (2002) Concomitant leflunomide in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Int Med 137: 726-36
13. Maddison P, Kiely P, Kirkham B et al (2004) Leflunomide in rheumatoid arthritis: recommendations through a process of consensus. Rheumatology (in press)
14. Malaviya R, Uckun FM (2001) Leflunomide metabolite analogue arpha-cyano-beta-hydroxy-beta-methyl-N-[3-(trifluoromethyl)]propenamide inhibits IgE/Fc epsilonRI receptor-mediated mast cell leukotriene release and allergic asthma in mice. Am J Therapeutics 8: 309-16
15. Metzler C, Low-Friedrich I, Reinhold-Keller E et al (1998) Leflunomide, a new promising agent in maintenance of remission in Wegener's granulomatosis. Clin Exp Immunol 112(suppl): 56
16. Osiri M, Shea B, Robinson V et al (2003) Leflunomide for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol 30: 1182-90
17. Prajapati DN, Knox JF, Emmons J, Saeian K, Csuka ME, Binion DG (2003) Leflunomide treatment of Crohn's disease patients intolerant to standard immunomodulator therapy. J Clin Gastroenterol 37: 125-8
18. Reich K, Hummel KM, Beckmann I, Moessner R, Neumann C (2002) Treatment of severe psoriasis and psoriatic arthritis with leflunomide. Br J Dermatol 146: 335-6
19. Remer CF, Weisman MH, Wallace DJ (2001) Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study. Lupus 10: 480-3
20. Rozman B (2002) Clinical pharmacokinetics of leflunomide. Clin Pharmacokinet 41: 421-30
21. Ruckemann K, Fairbanks L, Carrey E et al (1998) Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans. J Biol Chem 273: 21682-91
22. Sachar DB (2003) Leflunomide in Crohn's disease - the open label case series and the Texas sharpshooter. J Clin Gastroenterol 37: 99-100
23. Scott DL, Smolen JS, Kalden JR et al (2001) Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. Ann Rheum Dis 60: 913-23
24. Sinha A, Amos N, Lawson TM (2002) Leflunomide - the Welsh experience. Rheumatology 42: 97
25. Smolen JS, Kalden JR, Scott DL et al (1999) Efficacy and safety of leflunomide compared with placebo and sulfasalazine in active rheumatoid arthritis: a double blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 353: 259-66
26. Strand V, Cohen S, Schiff M et al (1999) Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Int Med 159: 2542-50
27. Yao HW, Li J, Jin Y et al (2003) Effect of leflunomide on immunological liver injury in mice. World J Gastroenterol 9: 320-3